BR112021025645A2 - Degradação de proteína alvo de parp14 para uso em terapia - Google Patents
Degradação de proteína alvo de parp14 para uso em terapiaInfo
- Publication number
- BR112021025645A2 BR112021025645A2 BR112021025645A BR112021025645A BR112021025645A2 BR 112021025645 A2 BR112021025645 A2 BR 112021025645A2 BR 112021025645 A BR112021025645 A BR 112021025645A BR 112021025645 A BR112021025645 A BR 112021025645A BR 112021025645 A2 BR112021025645 A2 BR 112021025645A2
- Authority
- BR
- Brazil
- Prior art keywords
- parp14
- therapy
- target protein
- protein degradation
- quinazolinones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 | |
| PCT/US2020/038377 WO2020257416A1 (en) | 2019-06-19 | 2020-06-18 | Targeted protein degradation of parp14 for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025645A2 true BR112021025645A2 (pt) | 2022-02-01 |
Family
ID=71527971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025645A BR112021025645A2 (pt) | 2019-06-19 | 2020-06-18 | Degradação de proteína alvo de parp14 para uso em terapia |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220388985A1 (enExample) |
| EP (1) | EP3986887A1 (enExample) |
| JP (2) | JP2022537349A (enExample) |
| KR (1) | KR20220024098A (enExample) |
| CN (2) | CN114206853A (enExample) |
| AU (1) | AU2020296063B2 (enExample) |
| BR (1) | BR112021025645A2 (enExample) |
| CA (1) | CA3142002A1 (enExample) |
| MA (1) | MA56513A (enExample) |
| SG (1) | SG11202112980TA (enExample) |
| WO (1) | WO2020257416A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2941818T3 (es) * | 2017-12-21 | 2023-05-25 | Ribon Therapeutics Inc | Quinazolinonas como inhibidores de PARP14 |
| WO2022150667A1 (en) * | 2021-01-08 | 2022-07-14 | The Board Of Regents Of The University Of Texas System | Nimbolide analogs and methods of use thereof |
| TW202241426A (zh) * | 2021-01-29 | 2022-11-01 | 美商律幫治療股份有限公司 | 治療發炎疾病之方法 |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| CN117229224B (zh) * | 2022-06-07 | 2026-05-08 | 中国药科大学 | 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用 |
| MA71624A (fr) | 2022-07-29 | 2025-05-30 | Abbvie Operations Singapore Pte. Ltd. | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
| KR20250055508A (ko) | 2022-07-29 | 2025-04-24 | 애브비 오퍼레이션즈 싱가포르 피티이. 리미티드 | 치료에 사용하기 위한 parp14의 표적 단백질 분해 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| WO2024251205A1 (zh) * | 2023-06-06 | 2024-12-12 | 西藏海思科制药有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| CN116813640A (zh) * | 2023-06-29 | 2023-09-29 | 成都金瑞基业生物科技有限公司 | 一类抑制并降解parp的化合物及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508414A (ja) * | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| EP2890696A1 (en) * | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| MY180775A (en) * | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| EP3535265A4 (en) * | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| EP3580212A4 (en) * | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| EP4310496A3 (en) * | 2017-07-12 | 2024-12-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| ES2941818T3 (es) * | 2017-12-21 | 2023-05-25 | Ribon Therapeutics Inc | Quinazolinonas como inhibidores de PARP14 |
-
2020
- 2020-06-18 KR KR1020217041538A patent/KR20220024098A/ko active Pending
- 2020-06-18 AU AU2020296063A patent/AU2020296063B2/en active Active
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/en not_active Ceased
- 2020-06-18 MA MA056513A patent/MA56513A/fr unknown
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/zh active Pending
- 2020-06-18 CN CN202510536711.9A patent/CN120398840A/zh active Pending
- 2020-06-18 CA CA3142002A patent/CA3142002A1/en active Pending
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/ja active Pending
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/en active Pending
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en not_active Abandoned
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/pt unknown
-
2025
- 2025-04-02 JP JP2025061199A patent/JP7844707B2/ja active Active
- 2025-05-22 US US19/216,120 patent/US20260125362A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7844707B2 (ja) | 2026-04-13 |
| MA56513A (fr) | 2022-04-27 |
| US20260125362A1 (en) | 2026-05-07 |
| EP3986887A1 (en) | 2022-04-27 |
| WO2020257416A1 (en) | 2020-12-24 |
| AU2020296063A1 (en) | 2021-12-23 |
| AU2020296063B2 (en) | 2026-01-29 |
| KR20220024098A (ko) | 2022-03-03 |
| SG11202112980TA (en) | 2021-12-30 |
| CN114206853A (zh) | 2022-03-18 |
| CA3142002A1 (en) | 2020-12-24 |
| CN120398840A (zh) | 2025-08-01 |
| US20220388985A1 (en) | 2022-12-08 |
| JP2022537349A (ja) | 2022-08-25 |
| JP2025102917A (ja) | 2025-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| BR112021024236A2 (pt) | Proteínas multiespecíficas | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| MX2023002507A (es) | Inhibidores de cd73. | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
| EA201890161A1 (ru) | Терапевтические композиции, комбинации и способы применения | |
| EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
| BR112015023207A2 (pt) | uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase | |
| EP4349997A3 (en) | Anti-garp antibody | |
| EA201792348A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
| CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
| PA8794201A1 (es) | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso | |
| EA201792509A1 (ru) | Лечение рака | |
| MX392789B (es) | Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112021019703A2 (pt) | Compostos heterocíclicos e usos dos mesmos | |
| MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
| CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| BR112022012283A2 (pt) | Combinações | |
| EP4273165A3 (en) | Interferon beta antibodies and uses thereof | |
| MX2022002337A (es) | Polipéptidos de tff2 modificados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |